{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:26:38Z","timestamp":1761625598940,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.dld.2021.09.007","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T19:18:50Z","timestamp":1632770330000},"page":"1117-1121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of 8 weeks elbasvir\/grazoprevir regimen for na\u00efve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study"],"prefix":"10.1016","volume":"54","author":[{"given":"Vincenza","family":"Calvaruso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"La Mantia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlando","family":"Gibilaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Reina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velia Chiara","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Licata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.09.007_bib0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"European Association for the Study of the Liver recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"year":"2017","series-title":"Global hepatitis report","key":"10.1016\/j.dld.2021.09.007_bib0002"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2021.09.007_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13668","article-title":"Is global elimination of HCV realistic?","volume":"38","author":"Calvaruso","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.09.007_bib0004","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.09.007_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2021.09.007_bib0006","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2147\/DDDT.S133697","article-title":"Safety and efficacy of elbasvir\/grazoprevir for the treatment of chronic hepatitis C: current evidence","volume":"12","author":"Morikawa","year":"2018","journal-title":"Drug Des, Dev Ther"},{"key":"10.1016\/j.dld.2021.09.007_bib0007","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00535-018-1429-3","article-title":"The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection","volume":"53","author":"Zeuzem","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2021.09.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14502","article-title":"Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for eight weeks in treatment-na\u00efve, HCV GT1b-infected patients, with non-severe fibrosis","author":"Abergel","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.09.007_bib0009","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2021.09.007_bib0010","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2021.09.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179562","article-title":"An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains","volume":"12","author":"Andre-Garnier","year":"2017","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.dld.2021.09.007_bib0012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/JCM.01784-12","article-title":"Second-generation Cobas AmpliPrep\/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design","volume":"51","author":"Zitzer","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.dld.2021.09.007_bib0013","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.09.007_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jiz154","volume":"220","author":"Huang","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.dld.2021.09.007_bib0015","doi-asserted-by":"crossref","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","article-title":"Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1-4 in Italy","volume":"8","author":"Bertoli","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2021.09.007_bib0016","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Ceccherini-Silberstein F. Drug Resist Updat."},{"key":"10.1016\/j.dld.2021.09.007_bib0017","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions","volume":"5","author":"Smolders","year":"2017","journal-title":"United Eur Gastroenterol J"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821007763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821007763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:19:10Z","timestamp":1761625150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821007763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1590865821007763"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.09.007","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of 8 weeks elbasvir\/grazoprevir regimen for na\u00efve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}